New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
13:39 EDTCS, VRX, AGNPershing Square enlists Credit Suisse to help in Allergan effort, WSJ says
William Ackman's Pershing Square has hired Credit Suisse (CS), which is a firm known to have expertise in defending corporate clients against activist investors, for advice on the effort to have Valeant Pharmaceuticals (VRX) take over Allergan (AGN), says the Wall Street Journal. Reference Link
News For AGN;VRX;CS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
06:19 EDTVRXPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.
April 21, 2015
05:45 EDTCSCredit Suisse sees momentum to carry over from Q1 into Q2
Subscribe for More Information
05:45 EDTCSCredit Suisse reports Q1 net income CHF 1.05B vs. CHF 859M
Reports Q1 core pre-tax income of CHF 1.54B. Reports Q1 revenue CHF 6.67B vs. CHF 6.47B last year. Reports look-through CET1 ratio of 10% as of the end of Q1.
April 15, 2015
10:19 EDTCSOptions with decreasing implied volatility
Subscribe for More Information
06:41 EDTCSECB authorizes new emergency funding for Greek banks, Reuters reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use